Olapali API

Name	Olapali
Chinese name	奥拉帕利
Cas Number	763113-22-0
Source	India
Qualifications	USDMF/-/-/-/-

Olapali is the first polyadenosine diphosphate ribose polymerase (PARP) inhibitor approved by the FDA. It was approved by the U.S. FDA in December 2014 for marketing. In August 2018, the China Food and Drug Administration officially approved Olapali. The listing in China has filled a gap in the domestic ovarian cancer targeted therapy field for nearly 30 years. PARP inhibitors inhibit the activity of PARP, causing large amounts of DNA damage when tumor cells divide, which ultimately leads to their death. Olapali is the leading product among PARP inhibitors. The drug is in a leading state in the expansion of multiple indications. It has expanded into three major categories of ovarian cancer (including fallopian tube cancer, peritoneal cancer), breast cancer and pancreatic cancer. Item indications. In 2019, it crossed the $1 billion blockbuster threshold. In addition, Olapa's application for new indications for the treatment of metastatic castration-resistant prostate cancer has also been granted priority review by the FDA and is expected to be approved in 2020.

Hot Tags: olapali api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Dapoxetine API, Fondaparinux API, Tippyridine Hydrochloride API, Linagliptin API, Deoxycholic Acid API, Lurasidone Hydrochloride API

• Previous: Carfilzomib API
• Next: Rebamipide API